Illumina

By Brian Dolan April 5, 2010
Apple began selling its new device, the iPad Saturday morning. Here's a quick round-up of some of the health and medical related posts from around the blogosphere about the device's launch: iFund looks to iPad, healthcare: One venture capital firm, Kleiner Perkins established a fund for iPhone applications a few years ago that is called the iFund. TechCrunch caught up with Kleiner Perkins...
By Brian Dolan October 28, 2009
At the TEDMED event here in San Diego this week, personal genomics company 23andMe co-founder Anne Wojcicki announced that the company now had more than 30,000 "active" genomes in its database and that it would soon launch a "Relative Finder" service for its users. As part of the new service, users can explore connections to other users of the site to determine how related they are to each other...
By Brian Dolan September 11, 2009
Source: Apple.com "The iPhone can be an integral part in advancing the fundamental science -- the very complexities of biology and understanding of the human genome can be made accessible through tools like the iPhone," Consumer genomics company Illumina's CEO and President, Jay Flatley told Apple in a recent interview. "I think it is the convergence of the science and IT technology that today...
By Brian Dolan June 10, 2009
At the Consumer Genetics Show in Boston today, genome sequencing company Illumina's President and CEO Jay Flatley announced that Illumina had partnered with four major direct-to-consumer genomics companies and demonstrated a very rough concept for a mobile application that leveraged a consumer's genomic profile.  Illumina inked partnerships with consumer-facing genome analysis services 23andme,...
By Brian Dolan June 10, 2009
At the Consumer Genetics Show in Boston, MA, today Illumina President and CEO Jay Flatley reveals an iPhone with a conceptualized application called MyGenome. Flatley said a developer at Illumina put the application together in just 10 days. MyGenome would include access to the user's entire genomic profile and relevant analysis of their variant genome. One section would be "pharmacogenomics...